University of Oulu

Junttila, A., Helminen, O., Väyrynen, J.P. et al. Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer. Br J Cancer 123, 1625–1632 (2020). https://doi.org/10.1038/s41416-020-01053-7

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

Saved in:
Author: Junttila, Anna1; Helminen, Olli1; Väyrynen, Juha P.2,3,4;
Organizations: 1Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland
2Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu, and Oulu University Hospital, Oulu, Finland
3Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
4Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA
5Department of Education and Research, Central Finland Health Care District, Jyväskylä, Finland
6MediCity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland
7Department of Education and Research, Central Finland Central Hospital and Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland
8Department of Pathology, Central Finland Central Hospital, Jyväskylä, Finland
9Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.6 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2021111755799
Language: English
Published: Springer Nature, 2020
Publish Date: 2021-11-17
Description:

Abstract

Background: Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1).

Methods: After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival.

Results: The 5-year overall survival rate was 43.4%. High ICS was associated with improved overall survival (adjusted HR 0.48 (95% CI 0.26–0.87)) compared to low ICS. In the high ICS group, patients with PD-L1 expression (5-year survival 69.2 vs. 53.1%, p = 0.317), high PD-1 (5-year survival 70.6 vs. 55.3% p = 0.312) and high Clever-1 (5-year survival 72.0% vs. 45.5% (p = 0.070) had poor prognosis.

Conclusions: High ICS was associated with improved survival. In the high ICS group, patients with high PD-L1, PD-1 and Clever-1 had poor prognosis highlighting the importance of immune escape and immune tolerance in GC.

see all

Series: British journal of cancer
ISSN: 0007-0920
ISSN-E: 1532-1827
ISSN-L: 0007-0920
Volume: 123
Pages: 1625 - 1632
DOI: 10.1038/s41416-020-01053-7
OADOI: https://oadoi.org/10.1038/s41416-020-01053-7
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
Funding: This study was funded by the Finnish State Research Funding (O.H.), the Instrumentarium Science Foundation (O.H.) and the Mary and Georg C. Ehrnrooth Foundation (O.H.).
Copyright information: © The Author(s), under exclusive licence to Cancer Research UK 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
  https://creativecommons.org/licenses/by/4.0/